Sigyn Therapeutics (OTCMKTS:SIGY) Issues Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) posted its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, Zacks reports.

Sigyn Therapeutics Stock Up 6.4%

Shares of OTCMKTS SIGY traded up $0.00 during midday trading on Thursday, hitting $0.03. The stock had a trading volume of 4,007 shares, compared to its average volume of 95,084. Sigyn Therapeutics has a 1-year low of $0.01 and a 1-year high of $5.00. The company has a market capitalization of $63,500.00, a price-to-earnings ratio of -0.01 and a beta of -0.08. The company has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.30.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.